Reprogramming of B cells into regulatory cells with engineered fusokines

Infectious Disorders - Drug Targets

Volumn 12, Issue 3, 2012, Pages 248-254

  Deng, Jiusheng ^a   Galipeau, Jacques ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bregs; Fusokine; GM CSF; IL 10; IL 15; Inflammation; Multiple sclerosis

Indexed keywords

CD1D ANTIGEN; CD22 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOKINE; GIFT15 PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; LEUKOSIALIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNDECAN 1; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ENGINEERING; CHEMICAL STRUCTURE; CHIMERA; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR REPROGRAMMING; REVIEW;

EID: 84861160853     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612800564392     Document Type: Review

References (68)

1. Cooper, M. D.; Peterson, R. D.; Good, R. A. Delineation of the Thymic and Bursal Lymphoid Systems in the Chicken. Nature, 1965, 205, 143-146.
2. Calame, K. L. Plasma cells: finding new light at the end of B cell development. Nat. Immunol., 2001, 2(12), 1103-1108.
3. Pierce, S. K.; Morris, J. F.; Grusby, M. J.; Kaumaya, P.; van Buskirk, A.; Srinivasan, M.; Crump, B.; Smolenski, L. A. Antigenpresenting function of B lymphocytes. Immunol. Rev., 1988, 106, 149-180.
4. Harris, D. P.; Haynes, L.; Sayles, P. C.; Duso, D. K.; Eaton, S. M.; Lepak, N. M.; Johnson, L. L.; Swain, S. L.; Lund, F. E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol., 2000, 1(6), 475-482.
5. Townsend, M. J.; Monroe, J. G.; Chan, A. C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev., 2010, 237(1), 264-283.
6. Blair, P. A.; Chavez-Rueda, K. A.; Evans, J. G.; Shlomchik, M. J.; Eddaoudi, A.; Isenberg, D. A.; Ehrenstein, M. R.; Mauri, C. Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J. Immunol., 2009, 182(6), 3492-3502.
7. Mizoguchi, A.; Mizoguchi, E.; Smith, R. N.; Preffer, F. I.; Bhan, A. K. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J. Exp. Med., 1997, 186(10), 1749-1756.
8. Mizoguchi, A.; Bhan, A. K. A case for regulatory B cells. J. Immunol., 2006, 176(2), 705-710.
9. Lund, F. E.; Randall, T. D. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat. Rev. Immunol., 2010, 10(4), 236-247.
10. Calderon-Gomez, E.; Lampropoulou, V.; Shen, P.; Neves, P.; Roch, T.; Stervbo, U.; Rutz, S.; Kuhl, A. A.; Heppner, F. L.; Loddenkemper, C.; Anderton, S. M.; Kanellopoulos, J. M.; Charneau, P.; Fillatreau, S. Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis. Eur. J. Immunol., 2011, 41(6), 1696-1708.
11. Fillatreau, S.; Sweenie, C. H.; McGeachy, M. J.; Gray, D.; Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol., 2002, 3(10), 944-950.
12. Wolf, S. D.; Dittel, B. N.; Hardardottir, F.; Janeway, C. A. Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med., 1996, 184(6), 2271-2278.
13. Goetz, M.; Atreya, R.; Ghalibafian, M.; Galle, P. R.; Neurath, M. F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel. Dis., 2007, 13(11), 1365-1368.
14. Dass, S.; Vital, E. M.; Emery, P. Development of psoriasis after B cell depletion with rituximab. Arth. Rheum., 2007, 56(8), 2715-2718.
15. Newell, K. A.; Asare, A.; Kirk, A. D.; Gisler, T. D.; Bourcier, K.; Suthanthiran, M.; Burlingham, W. J.; Marks, W. H.; Sanz, I.; Lechler, R. I.; Hernandez-Fuentes, M. P.; Turka, L. A.; Seyfert-Margolis, V. L. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest., 2010, 120(6), 1836-1847.
16. Hardy, R. R.; Hayakawa, K. B cell development pathways. Annu. Rev. Immunol., 2001, 19, 595-621.
17. Yanaba, K.; Bouaziz, J. D.; Haas, K. M.; Poe, J. C.; Fujimoto, M.; Tedder, T. F. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity, 2008, 28(5), 639-650.
18. Bouaziz, J. D.; Yanaba, K.; Tedder, T. F. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev., 2008, 224, 201-214.
19. Evans, J. G.; Chavez-Rueda, K. A.; Eddaoudi, A.; Meyer-Bahlburg, A.; Rawlings, D. J.; Ehrenstein, M. R.; Mauri, C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J. Immunol., 2007, 178(12), 7868-7878.
20. Ahuja, A.; Anderson, S. M.; Khalil, A.; Shlomchik, M. J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl. Acad. Sci. USA, 2008, 105(12), 4802-4807.
21. Blair, P. A.; Norena, L. Y.; Flores-Borja, F.; Rawlings, D. J.; Isenberg, D. A.; Ehrenstein, M. R.; Mauri, C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity, 2010, 32(1), 129-140.
22. Iwata, Y.; Matsushita, T.; Horikawa, M.; Dilillo, D. J.; Yanaba, K.; Venturi, G. M.; Szabolcs, P. M.; Bernstein, S. H.; Magro, C. M.; Williams, A. D.; Hall, R. P.; St Clair, E. W.; Tedder, T. F. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood, 2011, 117(2), 530-541.
23. Matsushita, T.; Yanaba, K.; Bouaziz, J. D.; Fujimoto, M.; Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest., 2008, 118(10), 3420-3430.
24. Matsushita, T.; Tedder, T. F. Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. Methods Mol. Biol., 2011, 677, 99-111.
25. Mackay, F.; Browning, J. L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol., 2002, 2(7), 465-475.
26. Bourke, E.; Bosisio, D.; Golay, J.; Polentarutti, N.; Mantovani, A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood, 2003, 102(3), 956-963.
27. Kurosaki, T.; Shinohara, H.; Baba, Y. B cell signaling and fate decision. Annu. Rev. Immunol., 2010, 28, 21-55.
28. Manicassamy, S.; Pulendran, B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol., 2009, 21(4), 185-193.
29. Yanaba, K.; Bouaziz, J. D.; Matsushita, T.; Tsubata, T.; Tedder, T. F. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol., 2009, 182(12), 7459-7472.
30. Lampropoulou, V.; Calderon-Gomez, E.; Roch, T.; Neves, P.; Shen, P.; Stervbo, U.; Boudinot, P.; Anderton, S. M.; Fillatreau, S. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol. Rev., 2010, 233(1), 146-161.
31. Yang, M.; Sun, L.; Wang, S.; Ko, K. H.; Xu, H.; Zheng, B. J.; Cao, X.; Lu, L. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol., 2010, 184(7), 3321-3325.
32. Kehry, M. R. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J. Immunol., 1996, 156(7), 2345-2348.
33. Duddy, M. E.; Alter, A.; Bar-Or, A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J. Immunol., 2004, 172(6), 3422-3427.
34. Harp, C. T.; Ireland, S.; Davis, L. S.; Remington, G.; Cassidy, B.; Cravens, P. D.; Stuve, O.; Lovett-Racke, A. E.; Eagar, T. N.; Greenberg, B. M.; Racke, M. K.; Cowell, L. G.; Karandikar, N. J.; Frohman, E. M.; Monson, N. L. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur. J. Immunol., 2010, 40(10), 2942-2956.
35. Mauri, C.; Gray, D.; Mushtaq, N.; Londei, M. Prevention of arthritis by interleukin 10-producing B cells. The Journal of experimental medicine, 2003, 197(4), 489-501.
36. Desai-Mehta, A.; Lu, L.; Ramsey-Goldman, R.; Datta, S. K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest., 1996, 97(9), 2063-2073.
37. Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev., 2004, 199, 227-250.
38. Stewart, C. R.; Stuart, L. M.; Wilkinson, K.; van Gils, J. M.; Deng, J.; Halle, A.; Rayner, K. J.; Boyer, L.; Zhong, R.; Frazier, W. A.; Lacy-Hulbert, A.; El Khoury, J.; Golenbock, D. T.; Moore, K. J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol., 2010, 11(2), 155-161.
39. Lampropoulou, V.; Hoehlig, K.; Roch, T.; Neves, P.; Calderon Gomez, E.; Sweenie, C. H.; Hao, Y.; Freitas, A. A.; Steinhoff, U.; Anderton, S. M.; Fillatreau, S. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol., 2008, 180(7), 4763-4773.
40. Brummel, R.; Lenert, P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J. Immunol., 2005, 174(4), 2429-2434.
41. Sun, C. M.; Deriaud, E.; Leclerc, C.; Lo-Man, R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity, 2005, 22(4), 467-477.
42. Bouaziz, J. D.; Calbo, S.; Maho-Vaillant, M.; Saussine, A.; Bagot, M.; Bensussan, A.; Musette, P., IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur. J. Immunol., 2010, 40(10), 2686-2691.
43. Scott, D. W. Gene therapy for immunological tolerance: using 'transgenic' B cells to treat inhibitor formation. Haemophilia, 2010, 16(102), 89-94.
44. Stagg, J.; Wu, J. H.; Bouganim, N.; Galipeau, J. Granulocytemacrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res., 2004, 64(24), 8795-8799.
45. Rafei, M.; Wu, J. H.; Annabi, B.; Lejeune, L.; Francois, M.; Galipeau, J. A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood, 2007, 109(5), 2234-2242.
46. Williams, P.; Rafei, M.; Bouchentouf, M.; Raven, J.; Yuan, S.; Cuerquis, J.; Forner, K. A.; Birman, E.; Galipeau, J. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol. Ther., 2010, 18(7), 1293-1301.
47. Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev., 2002, 188, 147-154.
48. Asao, H.; Okuyama, C.; Kumaki, S.; Ishii, N.; Tsuchiya, S.; Foster, D.; Sugamura, K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol., 2001, 167(1), 1-5.
49. Fehniger, T. A.; Caligiuri, M. A. Interleukin 15: biology and relevance to human disease. Blood, 2001, 97(1), 14-32.
50. Pettit, D. K.; Bonnert, T. P.; Eisenman, J.; Srinivasan, S.; Paxton, R.; Beers, C.; Lynch, D.; Miller, B.; Yost, J.; Grabstein, K. H.; Gombotz, W. R. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem., 1997, 272(4), 2312-2318.
51. Rafei, M.; Hsieh, J.; Zehntner, S.; Li, M.; Forner, K.; Birman, E.; Boivin, M. N.; Young, Y. K.; Perreault, C.; Galipeau, J. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med., 2009, 15(9), 1038-1045.
52. Corcoran, L. M. Transcriptional control of B cell activation. Curr. Top. Microbiol. Immunol., 2005, 290, 105-146.
53. Johnston, P. A.; Grandis, J. R. STAT3 signaling: anticancer strategies and challenges. Mol. Interv., 2011, 11(1), 18-26.
54. Correale, J.; Farez, M.; Razzitte, G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol., 2008, 64(2), 187-199.
55. Mizoguchi, A.; Mizoguchi, E.; Takedatsu, H.; Blumberg, R. S.; Bhan, A. K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity, 2002, 16(2), 219-230.
56. Tian, J.; Zekzer, D.; Hanssen, L.; Lu, Y.; Olcott, A.; Kaufman, D. L. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol., 2001, 167(2), 1081-1089.
57. Fillatreau, S.; Sweenie, C. H.; McGeachy, M. J.; Gray, D.; Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol., 2002, 3(10), 944-950.
58. Ronet, C.; Hauyon-La Torre, Y.; Revaz-Breton, M.; Mastelic, B.; Tacchini-Cottier, F.; Louis, J.; Launois, P. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J. Immunol., 2010, 184(2), 886-894.
59. Sayi, A.; Kohler, E.; Toller, I. M.; Flavell, R. A.; Muller, W.; Roers, A.; Muller, A., TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J. Immunol., 2011, 186(2), 878-890.
60. Wei, B.; Velazquez, P.; Turovskaya, O.; Spricher, K.; Aranda, R.; Kronenberg, M.; Birnbaumer, L.; Braun, J., Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl. Acad. Sci. USA, 2005, 102(6), 2010-2015.
61. Mann, M. K.; Maresz, K.; Shriver, L. P.; Tan, Y.; Dittel, B. N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol., 2007, 178(6), 3447-3456.
62. Lundy, S. K.; Fox, D. A. Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res. Ther., 2009, 11(4), R128.
63. Sun, J. B.; Flach, C. F.; Czerkinsky, C.; Holmgren, J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol., 2008, 181(12), 8278-8287.
64. Kennedy, M. W.; Thomas, D. B. A regulatory role for the memory B cell as suppressor-inducer of feedback control. J. Exp. Med., 1983, 157(2), 547-558.
65. Shimamura, T.; Habu, S.; Hashimoto, K.; Sasaki, S. Feedback suppression of the immune response in vivo. III. Lyt-1+ B cells are suppressor-inducer cells. Cell Immunol., 1984, 83(1), 221-224.
66. Rowe, V.; Banovic, T.; MacDonald, K. P.; Kuns, R.; Don, A. L.; Morris, E. S.; Burman, A. C.; Bofinger, H. M.; Clouston, A. D.; Hill, G. R. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood, 2006, 108(7), 2485-2492.
67. Michonneau, D.; Peffault de Latour, R.; Porcher, R.; Robin, M.; Benbunan, M.; Rocha, V.; Ribaud, P.; Ferry, C.; Devergie, A.; Vanneaux, V.; Gluckman, E.; Marolleau, J. P.; Socie, G.; Larghero, J. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br. J. Haematol., 2009, 145(1), 107-114.
68. Yanaba, K.; Yoshizaki, A.; Asano, Y.; Kadono, T.; Tedder, T. F.; Sato, S. IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am. J. Pathol., 2011, 178(2), 735-743.